Sunshine Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on March 12, 2019, by Sunshine Biopharma Inc., a Colorado-based emerging growth company. The report discloses the commercial availability of the company's new dietary supplement product, Essential 9TM, following regulatory authorization.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on operational milestones rather than financial performance.
Material Changes and Operational Updates
- Regulatory Approval: On December 14, 2018, Health Canada issued Natural Product Number (NPN) 80089663, authorizing the manufacture and sale of Essential 9TM.
- Product Launch: Essential 9TM, a tablet containing a balanced formula of 9 essential amino acids, is now available for purchase on Amazon.ca.
- Product Description: The supplement addresses deficiencies in essential amino acids that the human body cannot produce, which can lead to muscle mass loss and fatigue.
Guidance, Outlook, and Risks
- Future Availability: Management anticipates that Essential 9TM will soon be available on Amazon.com, though no assurances are provided regarding the timeline.
- Risks: The filing explicitly states that no assurances can be provided regarding the future availability of the product on U.S. platforms.
Key Facts for Investor Verification
- Verify the actual sales volume and revenue generated from the Amazon.ca launch.
- Confirm the timeline and regulatory requirements for listing the product on Amazon.com.
- Review the company's cash position to ensure sufficient liquidity to support manufacturing and marketing of the new product.
- Check for any subsequent filings regarding the U.S. launch status.